Currently MDA is stopped when TF in children aged 1-9 years is below 5%. However, the relationship between TF, presence of infection and antibody has not been studied in a sufficient number of settings to enable predictions of outcome to be confidently made based on baseline prevalence, intervention coverage, and the prevalence of disease and infection at the time of impact survey. There are several districts in Malawi with TF prevalence between 5 and 9.9% which are eligible for one year of interventions, including a single round of MDA. This study will add important data to be used to model outcomes of interventions conducted by trachoma elimination programs, and in particular, help develop operational guidelines for stopping MDA.
To test alternative rapid diagnostic test (RDT) formats for the Wb123 rapid test. In field trials, the current test format was less sensitive that FTS in post-MDA settings whereas alternative Wb123 test formats (ELISA, multiplex) were more sensitive. Our group uses new detection systems, based on nanoshells, to improve RDT performance.
To define a cost-effective strategy to map Ivermectin-naïve districts for Onchocerciasis, Lymphatic Filariasis, and Loiasis in the context of elimination of these NTDs
Integrated Transmission Assessment Surveys (iTAS) and Onchocerciasis evaluation in areas of Co-Endemicity for both infections in Tanzania
To determine the validity and programmatic feasibility of an integrated transmission assessment survey (F-TAS), to be used to simultaneously assess Onchocerciasis (Oncho) and Lymphatic Filariasis (LF) prevalence in areas co-endemic for the two infections that have completed the recommended treatment for one or both infections.
To determine if a standardized multi-parallel-PCR assay is a more sensitive diagnostic tool for detecting Hookworm (Ancylostoma duodenale and Necator americanus), Trichuris trichiura, Ascaris lumbricoides, Strongyloides stercoralis, and Schistosoma mansoni prevalence compared to the Kato-Katz stool test.
To define a cost-effective and accurate method to map ivermectin-naïve districts for Onchocerciasis, Lymphatic Filariasis and Loiasis and identify districts eligible for safe treatment with ivermectin MDA.
Estimating Population Denominators and Coverage of Mass Drug Administration Using Polio’s Vaccination Tracking System
To determine the viability of utilizing the polio program’s Vaccination Tracking System (VTS) to generate more accurate population, drug requirement and coverage estimates in NTD programs